South Church Street PO Box 309
George Town KY1-1104
Full Time Employees: 158
|Mr. Rick E. Winningham M.B.A.||Chairman & CEO||1.05M||N/A||1960|
|Mr. Andrew Asa Hindman M.B.A||Sr. VP & CFO||575.39k||N/A||1973|
|Ms. Rhonda F. Farnum||Chief Bus. Officer and Sr. VP of Commercial & Medical Affairs||435.52k||N/A||1965|
|Dr. Richard A. Graham Ph.D.||Sr. VP of R&D||469.44k||N/A||1974|
|Ms. Gail B. Cohen||VP of Corp. Communications & Investor Relations||N/A||N/A||N/A|
|Mr. Brett A. Grimaud Esq.||Sr. VP, Gen. Counsel & Sec.||N/A||N/A||N/A|
|Ms. Stacy L. Pryce||Sr. VP & Chief Strategy Officer||N/A||N/A||N/A|
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; Nezulcitinib, a lung-selective, nebulized JAK inhibitor, which is in Phase II clinical development for the potential treatment of hospitalized patients with acute lung injury caused by COVID-19; Inhaled ALK5i, a potential inhaled anti-fibrotic agent that is in Phase I for the treatment of idiopathic pulmonary fibrosis; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY for the treatment of COPD and asthma; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Viatris Inc., Janssen Biotech, Inc., Alfasigma S.p.A, and Takeda Pharmaceutical Company Limited. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.
Theravance Biopharma, Inc.’s ISS Governance QualityScore as of October 1, 2022 is 6. The pillar scores are Audit: 7; Board: 5; Shareholder Rights: 7; Compensation: 8.